Phase 4 N=20 Aczone Gel 7.5% in the Treatment of Acne Vulgaris in Patients With Skin of Color
Acne Vulgaris
Primary: Mean Change From Baseline to Week 12 in Global Acne Assessment Score (GAAS) — -0.86 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=104 Improvisational Movement for People With Memory Loss and Their Caregivers
Alzheimer's Disease (Incl Subtypes) · Dementia · Mild Cognitive Impairment
Primary: Quality of Life in Alzheimer's Disease (QOL-AD)--Participants With Dementia (PWD) — 35.42; 38.10; 35.56; 36.12 score on a scale
N/A N=654 Multicenter Clinical Trial of a Phakic Implantable Collamer® Lens (ICL)
Myopia · Myopic Astigmatism
Primary: Number of Primary Eyes Requiring Peripheral Iridotomy (PI) — 0 eyes
Phase 4 N=180 Minimal Opioid Use After Total Hip Replacement (THR)
Osteoarthritis, Hip
Primary: Opioid Use — 30; 22.5; 15 Oral Morphine Equivalent (mg)
Phase 2 N=22 TXA127 for the Treatment of Severe COVID-19
COVID-19
Primary: Change of Serum Creatinine — 0.92; 0.70 mg/dL
Phase 4 N=160 Multimodal Uterotonics at the Time of Cesarean Section in Laboring Patients
Uterine Atony With Hemorrhage
Primary: Number of Participants With Need for Additional Uterotonics (Methylergonovine, Carboprost, Misoprostol) — 80; 80 Participants
Phase 2 N=35 PTH(1-34) and Pelvic Fracture Healing - a Randomized Controlled Trial
Osteoporotic Fractures
Primary: Number of Participants With Evidence of Cortical Bridging for Fracture Healing — 9; 8 Participants
Phase 2 N=201 Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV
Respiratory Syncytial Virus Infections
Primary: Number of Subjects With Any Solicited Local Adverse Events (AEs) During a 7-day Follow-up Period After the First Vaccination (Administered at Day 1) — 5; 6; 0; 22…
N/A N=333 BAILA: Being Active, Increasing Latinos Healthy Aging
Mobility Limitation
Primary: Minutes Per Week of Moderate to Vigorous Physical Activity — 156.84; 86.84 Change in minutes/week
Phase 4 N=79 Liposomal Bupivacaine Interscalene Blocks for Rotator Cuff Repair
Acute Pain
Primary: Total Intraoperative Opioids Used — .1; .1; 30; 30 mg
Phase 3 N=283 Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants
Anemia Associated With End Stage Renal Disease
Primary: Percentage of Participants With Mean Hb Value ≥10 g/dL — 83.7 percentage of participants
Early Phase 1 N=8 Effect of Probenecid on Synovial Fluid ATP Levels in CPPD
Calcium Pyrophosphate Deposition Disease
Primary: ATP Levels in Synovial Fluid — 4.4; 31.4 nanomoles/ml
Phase 2 N=12 NeuroCovid Rehab and Recovery Related to COVID-19 Diagnosis
Coronavirus · Covid19
Primary: Change in Score of Patient Health Questionnaire-9 — -8.7; -5.5 score on a scale
Phase 3 N=101 Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency Disorder
CDKL5 Deficiency Disorder
Primary: Summary of 28-day Seizure Frequency for Major Motor Seizure Types — 49.17; 54.00; 55.50; 45.03 Seizures per day
Phase 2 N=58 Cefixime for Alternative Syphilis Treatment
Syphilis · Early Syphilis
Primary: Treatment Response — 14; 13 Participants